The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 526-536

  Ihbe Heffinger, Angela ^a   Ehlken, B ^b   Bernard, R ^a   Berger, K ^b   Peschel, C ^a   Eichler, H G ^c,d   Deuson, R ^c   Thodtmann J ^a   Lordick, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Medical Economics Research Group   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy induced nausea and vomiting; Cost of illness; Health economics; Healthcare provider; Healthcare utilization; Third party payer

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; GERMANY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; NAUSEA; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; WORKING TIME;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DRUG COSTS; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; VOMITING;

EID: 1842607574     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh110     Document Type: Review

References (24)

1. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
2. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-2994.
3. O'Brien BJ, Rusthoven J, Rocci A et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: Survey of five Canadian centres. Can Med Assoc J 1993; 149: 296-302.
4. Uyl-de Groot CA, Wait S, Buijt I. Economics and health-related quality of life in antiemetic therapy: Recommendations for trial design. Eur J Cancer 2000; 36: 1522-1535.
5. Herold M, Hieke K. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econom 2002; 3: 166-172.
6. Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. DCTD, NCI, NIH and DHHS, March 1998; [online] www.ctep.cancer.gov/forms/ctcv2nom-4-30-99-final3.pdf (date last accessed: July 2003).
7. Hannoveraner Konsens Gruppe. Dt. Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens. Gesundheitsökonomie Qualitätsmanagement 1999; 4: A62-A65.
8. Scherbel G, Bodenmüller-Kroll R, Matthias M et al. Antiemetische Therapieformen Kosten und Effektivität im Vergleich. Arzneimitteltherapie 1994; 6 (Suppl 17): 1-8.
9. Beckwith MC, Mullin S. Prevention and management of chemotherapy-induced nausea and vomiting, part 1. Hospital Pharmacy 2001; 36: 67-82.
10. Mertens WC, Higby DJ, Brown D et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 2003; 21: 1373-1378.
11. Roila F, Donati D, Tamberi S et al. Delayed emesis: Patterns, prognostic factors and optimal treatment. Support Care Cancer 2002; 10: 88-95.
12. Warr D. Standard treatment of chemotherapy-induced emesis. Support Care Cancer 1997; 5: 12-16.
13. 3 era: A national survey of hematologists/oncologists. Proc Am Soc Clin Oncol 2002; 21: 260 (Abstr 2860).
14. Roila F. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. Italian Group for Antiemetic Research. N Engl J Med 2000; 342: 1554-1559.
15. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000; 20: 113-121.
16. Bonneterre J, Hecquet B, Atenis A et al. How do patients and physicians decide which antiemetic is best in a cross over study? Proc Am Soc Clin Oncol 1991: 10: 323 (Abstr 1136).
17. Lecomte S, Lemenager M, Duquenne I et al. Quality of life in breast cancer patients receiving adjuvant chemotherapy. Proc Am Soc Clin Oncol 1995: 14: 308 (Abstr 900).
18. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995; 76: 343-357.
19. Lindley CM, Hirsch JD, O'Neill CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-340.
20. Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 1172-1177.
21. 3 receptor antagonists in moderately emetogenic chemotherapy. A prospective pharmacoeconomic evaluation in German hospitals: Eur J Cancer 2000; 36 (Suppl 3): 18.
22. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Cost of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 1999; 17: 344-351.
23. Hayman JA, Langa KM, Kabeto MU et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol 2001; 19: 3219-3225.
24. Lindley CM, Hirsch JD. Nausea and vomiting and cancer patients' quality of life: A discussion of professor Selby's paper. Br J Cancer 1992; 66 (Suppl XIX): S26-S29.